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The tumor suppressor PTEN, a critical regulator
formultiple cellular processes, ismutatedor de-
leted frequently in various human cancers. Sub-
tle reductions in PTEN expression levels have
profound impacts on carcinogenesis. Here we
show that PTEN level is regulated by ubiquitin-
mediated proteasomal degradation, and puri-
fied its ubiquitin ligase as HECT-domain protein
NEDD4-1. In cells NEDD4-1 negatively regulates
PTEN stability by catalyzing PTEN polyubiquiti-
nation. Consistent with the tumor-suppressive
role of PTEN, overexpression of NEDD4-1 po-
tentiated cellular transformation. Strikingly, in
amouse cancermodel andmultiple human can-
cer samples where the genetic background
of PTEN was normal but its protein levels were
low, NEDD4-1 was highly expressed, suggest-
ing that aberrant upregulation of NEDD4-1 can
posttranslationally suppress PTEN in cancers.
Elimination of NEDD4-1 expression inhibited
xenotransplanted tumor growth in a PTEN-
dependent manner. Therefore, NEDD4-1 is a
potential proto-oncogene that negatively regu-
lates PTENvia ubiquitination, a paradigmanalo-
gous to that of Mdm2 and p53.
INTRODUCTION
The tumor suppressor PTEN plays critical roles in cell
growth, migration, and death (Di Cristofano et al., 1998;
Raftopoulou et al., 2004; Sansal and Sellers, 2004; Stam-
bolic et al., 1998; Tamura et al., 1998). It is mutated or de-
leted with high frequency in various human cancer tissues
to promote tumorigenesis (Li et al., 1997; Sansal and
Sellers, 2004; Steck et al., 1997).Mousemodels for human
cancer revealed that PTEN is haploinsufficient (Kwabi-Addo et al., 2001; Trotman et al., 2003). Molecularly,
PTEN is a phosphatase for second-messenger phosphati-
dyl inositol-3,4,5-triphosphate (PIP3) (Maehama et al.,
2001; Sansal and Sellers, 2004; Stambolic et al., 1998),
which is required for activation of kinase AKT/PKB as
well as the downstream cellular survival and growth re-
sponses (Luo et al., 2003).
The crucial function of PTEN in multiple cellular pro-
cesses and its involvement in human diseases suggest
that the enzyme needs to be deliberately regulated in vivo.
This notion is supported by a recent genetic study showing
quantitatively that subtle decreases of PTEN expression in
mice predispose to tumorigenesis and accelerate cancer
progression (Trotman et al., 2003). Gene deletion and
mutation of PTENoccur frequently during cancer develop-
ment. These genetic changes, however, are not necessar-
ily the only ways to inactivate PTEN during tumorigenesis:
a defect in posttranslational regulation might also be able
to suppress this important tumor suppressor.
Previous reports indicate that PTEN is indeed regulated
by multiple posttranslational mechanisms. For example, a
repressor of PTEN named DJ-1 was genetically isolated
recently from Drosophila (Kim et al., 2005). However,
how this potential oncoprotein represses PTEN function
biochemically is not clear. PTEN has been shown to be
phosphorylated in cells, and the phosphorylation appears
to affect PTEN function (Adey et al., 2000; Leslie and
Downes, 2004; Torres and Pulido, 2001; Vazquez et al.,
2000). Again, the mechanisms that regulate PTEN phos-
phorylation and dephosphorylation as well as the exact
mechanisms by which PTEN phosphorylation impacts its
function are not clear.
In addition, PTEN might also be regulated by ubiquitin-
mediated proteasomal degradation, which is a common
mechanism to control protein levels posttranslationally
(Ciechanover et al., 1984; Hershko and Ciechanover,
1998). PTEN has two canonical PEST motifs, which is a
signature in many short-lived proteins degraded by the
ubiquitin pathway (Rogers et al., 1986), and treatment of
cells with proteasome inhibitors can cause an increase
of PTEN protein level (Torres and Pulido, 2001; Wu et al.,Cell 128, 129–139, January 12, 2007 ª2007 Elsevier Inc. 129
2003). These results prompted us to investigate the role of
ubiquitin-mediated proteasomal degradation in regulation
of PTEN. In this study, we report identification of the ubiq-
uitin ligase (E3) for PTEN and its roles in regulating PTEN
and tumorigenesis.
RESULTS
In Vivo and In Vitro PTEN Ubiquitination
We first examined whether PTEN is ubiquitinated in cells.
293T cells were cotransfected with plasmids encoding
for His-tagged PTEN and HA-tagged ubiquitin. The ex-
pressed His-tagged PTEN was specifically pulled down
from cell lysates by Ni2+-NTA beads, and nonspecific pro-
teins and indirectly associatedproteinswerewashedaway
using 6 M guanidine as reported (Treier et al., 1994). Sub-
sequently, immunoblotting against HA-tag was performed
todetect ubiquitinatedPTEN (Figure 1A).We found that the
overexpressed PTEN was polyubiquitinated and that the
polyubiquitinated PTEN was the substrate for protea-
somes because treatment of cells with the proteasome
inhibitor MG132 caused a robust increase of PTEN poly-
ubiquitination (Figure 1A).
We developed a biochemical assay that can detect
polyubiquitination of PTEN in vitro. We used recombinant
GST-tagged PTEN as the substrate. After incubation with
recombinant ubiquitin-activating enzyme (E1), ubiquitin-
conjugating enzyme UbcH5C or UbcH7 (E2), ATP, ubiqui-
tin, and HeLa cell cytosolic protein fraction (HeLa S-100 or
HS100) as indicated (Figure 1B), GST-PTEN was pulled
down by glutathione Sepharose, and polyubiquitination
of GST-PTEN was analyzed by immunoblotting against
ubiquitin. In such an assay, we observed HS100-depen-
dent polyubiquitination of GST-PTEN (Figure 1B, lane 6)
but not of GST (Figure 1B, lane 7). Requirement of HS100
indicates that HS100 provides an E3 activity for PTEN.
Purification and Identification of the E3 for PTEN
In the polyubiquitination process, the substrate specificity
is conferred by E3s (Ciechanover et al., 1984; Hershko and
Ciechanover, 1998). E3s are also the crucial targets for
biological regulation of the process (Ciechanover et al.,
1984; Hershko and Ciechanover, 1998). Therefore, we
set out to purify and identify the E3 for PTEN from HS100
by using the in vitro assay we developed. After a seven-
step purification concludingwithMonoQchromatography
(Figure 2A), we obtained strong E3 activity for PTEN (frac-
tions 9 and 10, Figure 2B) that correlated with a single pro-
tein band stained with silver in SDS-PAGE (Figure 2C). The
size of this protein is 110 to 120 kDa. The purified E3 activ-
ity could support polyubiquitination of recombinant PTEN
with a C-terminal HA-tag (Figure 2D, detected by an anti-
HAantibody) thus rulingout anypossible artifact thatmight
be caused by the bulky GST tag of GST-PTEN.
Subsequently, we conducted mass spectrometry (MS)
analysis (MALDI-TOF-MS/MS) to determine the identity
of the purified PTEN E3. The mass fingerprinting matched
human protein NEDD4-1 (neural precursor cell expressed,130 Cell 128, 129–139, January 12, 2007 ª2007 Elsevier Inc.developmentally downregulated-4-1), which is a putative
E3 containing a HECT domain.
It appears that the NEDD4-1 cDNA used in earlier pub-
lications all missed the N terminus of the open reading
frame (ORF). We thus deduced the complete ORF based
on human genomic sequence and subsequently cloned
it by connecting the coding region for its N terminus
(from HeLa cells by genomic PCR) with the overlapping
C-terminal part (from KIAA0093 clone; Nagase et al.,
1995). The full-length NEDD4-1 protein contains several
functional motifs (Figure 2E). In the N terminus, there are
a proline-rich domain and a polyserine motif followed by
a C2 domain. NEDD4-1 also contains four WW domains
in the middle and the signature E3 domain, the HECT do-
main, in the C terminus.
NEDD4-1 can interact with PTEN in cells as shown by
coimmunoprecipitation analysis (Figure 2F). Further, in an
in vitro GST pull-down experiment, GST-PTEN but not
GST alone pulled down purified NEDD4-1 (Figure 2G).
Therefore, the interaction of NEDD4-1 with PTEN is direct.
NEDD4-1 but Not NEDD4-2 Can Ubiquitinate PTEN
NEDD4-1 has a close homolog, NEDD4-2 (Figure S1). The
human genomic loci of these two homologs are different:
Figure 1. Polyubiquitination of PTEN In Vivo and In Vitro
(A) Polyubiquitination of transfected PTEN. C-terminal His-tagged
PTEN was cotransfected with HA-tagged ubiquitin (HA-Ub) in 293T
cells as indicated. The cells were treated with or without 25 mMprotea-
some inhibitor MG132 for 6 hr and then harvested and lysed. His-
tagged PTEN was pulled down with Ni2+ beads, washed with 6 M
guanidine as described in Experimental Procedures, and subjected
to immunoblotting against HA-tag to detect ubiquitinated PTEN.
(B) In vitro ubiquitination of PTEN. The in vitro assay was performed as
described in Experimental Procedures with individual components
added as indicated. GST-PTEN was used as the substrate, and
HS100 (5 ml and 5 mg protein/ml) was required to provide the PTEN
ubiquitin ligase (E3) activity.
Figure 2. Purification and Identification
of the PTEN E3 as NEDD4-1
(A) The purification scheme. The detailed pro-
cedure was described in Experimental Proce-
dures.
(B) The PTEN E3 activity in fractions (Fraction,
2 ml each) from the final Mono Q column was
measured by the in vitro PTEN ubiquitination
assay.
(C) The final Mono Q fractions (15 ml each) were
resolved by SDS-PAGE and stained with silver.
(D) The purified PTEN E3 activity can ubiquiti-
nate HA-tagged recombinant PTEN. The puri-
fied E3 (2 ml) or HS100 (5 ml) was used in the
reactions as indicated. The ubiquitinated
PTENwas detected by immunoblotting against
HA-tag.
(E) The domain structure of NEDD4-1. Amino
acid positions of individual domains are de-
noted by corresponding numbers.
(F) Interaction of NEDD4-1 with PTEN in 293T
cells determined by coimmunoprecipitation
analysis. PTEN and HA-tagged NEDD4-1 (N4-
HA) were transfected as indicated. After immu-
noprecipitation using anti-HA antibody, PTEN
and N4 were detected in the precipitates by
immunoblotting (upper two panels). The cell ly-
sate was blotted for N4, PTEN, and tubulin be-
fore immunoprecipitation (lower three panels)
as a control.
(G) Direct physical interaction of PTEN with
NEDD4-1 (N4) determined by a GST pull-
down assay. GST-PTEN but not GST alone
pulled down purified NEDD4-1.15q21 for NEDD4-1 and 18q21 for NEDD4-2. Although the
mass fingerprinting of NEDD4-1 did not match with that of
NEDD4-2, there were two peptide sequences obtained
from the MS analysis that existed in both proteins (Fig-
ure S1). To check whether there was NEDD4-2 in our pu-
rified PTEN E3 fraction, we performed immunoblotting
analysis using antibodies that can distinguish between
human NEDD4-1 and NEDD4-2 (Kamynina et al., 2001).
Although both proteins could be clearly detected in
HS100, only NEDD4-1 but not NEDD4-2 was detected in
the purified PTEN E3 fraction (Figure 3A). Further, using an
anion-exchange Mono Q column, we separated NEDD4-1
from NEDD4-2 in HS100 and found that the NEDD4-1
fractions but not the NEDD4-2 fractions contained E3
activity for PTEN (Figure 3B). Therefore, NEDD4-1 but
not NEDD4-2 can function as the E3 for PTEN.
NEDD4-1 Can Ubiquitinate PTEN in Cells
We confirmed the role of NEDD4-1 as PTEN E3 in cells.
293T cells were cotransfected with His-tagged PTEN
and HA-ubiquitin in the presence or absence of NEDD4-
1 overexpression. Overexpression of NEDD4-1 in 293T
cells caused an increase of PTEN polyubiquitination in a
NEDD4-1 dose-dependent manner (Figures 4A and S2).As expected, a high level of NEDD4-1 overexpression
also caused a decrease of endogenous PTEN protein in
293T cells. Such a decrease of PTEN protein level can
be blocked by proteasomal inhibitor MG132 (Figure 4B).
Further, we showed that NEDD4-1 overexpression can
stimulate polyubiquitination of endogenous PTEN in
293T cells (Figure 4C, lane 3), and the NEDD4-1-catalyzed
PTEN polyubiquitination can be further enhanced by treat-
ment of MG132 (Figure 4C, lane 4). These results indicate
that NEDD4-1 can polyubiquitinate endogenous PTEN
and thereby target PTEN to proteasomal degradation.
Using RNAi approach, we demonstrated quantitatively
that endogenous NEDD4-1 negatively regulates PTEN
levels (Figures 4D and 4E). We generated several shRNA
constructs (iN4 plasmids) against human NEDD4-1.
Among them, iN4Aand iN4Bcan strongly andmodestly re-
duce NEDD4-1 expression, respectively, while iN4C has
no effect (Figure 4D). Consistently, iN4A and iN4B caused
high and modest increase of PTEN protein level, but iN4C
failed to increase PTEN in cells (Figure 4E).
We further showed that negative regulation of PTEN
steady-state level by NEDD4-1 is indeed through modu-
lating PTEN degradation. To examine the rate of PTEN
degradation, PTEN was cotransfected with plasmids forCell 128, 129–139, January 12, 2007 ª2007 Elsevier Inc. 131
NEDD4-1 overexpression or RNAi knockdown. Subse-
quently, protein translation in cells was inhibited by cyclo-
heximide treatment, and PTEN protein levels were
detected at the indicated times of treatment. As shown
in Figures 4F and 4G, overexpression of NEDD4-1 and
RNAi knockdown of NEDD4-1 caused an increase in and
a decrease of PTEN degradation rate, respectively.
Taken together, we conclude that NEDD4-1 is a physio-
logical E3 for PTEN that targets PTEN to proteasomal deg-
radation.
NEDD4-1 Regulates Tumorigenesis
PTEN is a potent tumor suppressor that negatively regu-
lates the PI3K-Akt pathway. Therefore, the E3 of PTEN,
NEDD4-1, might function as an oncogene. To test this
possibility, we first determined whether endogenous
NEDD4-1 can regulate AKT signaling via PTEN (Figure 5A).
Indeed, knockdown of NEDD4-1 by RNAi in 293 cells
caused an increase in endogenousPTENanda concurrent
decrease of AKT phosphorylation. Further, we performed
soft-agar colony-formation assays in p53/ primary
Figure 3. NEDD4-1 but Not NEDD4-2 Is an E3 for PTEN
(A) NEDD4-1 but not NEDD4-2 was presented in the purified PTEN E3
fraction. Different volumes of HS100 (5 mg protein/ml) and purified
PTEN E3 activity (E3) were subjected to immunoblot against NEDD4-
1 and NEDD4-2 as indicated.
(B) NEDD4-1 fractions but not NEDD4-2 fractions possess PTEN E3
activity. NEDD4-1 and NEDD4-2 in HS100 were separated by Mono
Q chromatography as shown by immunoblotting (top panel). The
PTEN E3 activity in 5 ml of individual fractions (fractions 13 and 14 as
NEDD4-1 fractions; fractions 19 and 20 as NEDD4-2 fractions; fraction
11 as a negative control) was measured (bottom panel).132 Cell 128, 129–139, January 12, 2007 ª2007 Elsevier Inc.mouse embryonic fibroblasts (MEFs) (Jacks et al., 1994;
Pao et al., 2003) to measure the cell-transforming ability
of NEDD4-1. In Figure 5B, we confirmed that overexpres-
sion of NEDD4-1 could cause a decrease of PTEN in the
p53/ primary MEFs. In soft-agar colony-formation ex-
periments, although overexpression of NEDD4-1 alone
did not induce transformation, it dramatically enhanced
the oncogenic capability of oncogenic K-Ras, as shown
by an increase of both number and size of cell colonies
comparedwith that caused byK-Ras alone (Figure 5C). In-
triguingly, NEDD4-1 coexpression with K-Ras reproduc-
ibly resulted in a larger number but smaller size of colonies
than that caused by coexpression of Myc with Ras (data
not shown). This suggests that cooperation of NEDD4-1
with Ras might provide greater survival advantage but
less growth advantage than Myc-Ras cooperation.
To examine whether such oncogenic activity of NEDD4-
1 is PTEN dependent, we performed the same colony-
formation assays in p53+/Pten/ primary MEFs (Chen
et al., 2005). In such a Pten null background, NEDD4-1
overexpression failed to enhance the transforming activity
of Ras (Figures 5D and S3). Therefore, the oncogenic
activity of NEDD4-1 is PTEN dependent.
To determine whether the oncogenic function of
NEDD4-1 is relevant physiologically to cancer develop-
ment, we utilized a mouse model that has a hypomorphic
allele and a null allele of Pten (Ptenhy/) (Chen et al., 2005;
Trotman et al., 2003). Prostates in Ptenhy/ mice have a
PTEN protein level of only 30% compared to that in
wild-type mice and display accelerated prostate tumori-
genesis compared to Pten+/ mice (Trotman et al.,
2003). Intriguingly, tumors consistently arise from single
glands that contain lower PTEN protein levels than their
noncancerous neighbors and proliferate more rapidly
(Figure 6A). This further decrease of PTEN protein in the
tumor lesions, which is likely an initiating oncogenic event,
was not caused by loss of the hypomorphic Pten allele be-
cause a low level of PTEN protein is always clearly detect-
able (Figure 6A). To test if it was caused by overexpression
of NEDD4-1 and subsequent accelerated PTEN degrada-
tion, we performed immunohistochemistry (IHC) staining
of such early prostate lesions. Neoplastic areas of
Ptenhy/ prostates are easily identified by strong phos-
pho-Akt staining (Figure 6A; p-Akt, tm), and these glands
invariably display lower PTEN levels than the normal
ones (Figure 6A; Pten, tm versus nl). Importantly, by using
an antibody that is specific for NEDD4-1 (Figure S4),
NEDD4-1 levels were found to be consistently higher in
areas of low PTEN (Figure 6A; N4, tm versus nl), which
strongly suggests that NEDD4-1 dictates PTEN protein
levels in these tissues and thus is a key regulator of tumor-
igenesis in prostate.
We then studied the clinical relevance of NEDD4-1 in
human cancers. Previously we found that certain human
bladder cancer carcinomas with normal PTEN mRNA
levels displayed surprisingly low to undetectable PTEN
protein expression. In light of the function of NEDD4-1
as PTEN E3, we hypothesized that overexpression of
Figure 4. Regulation of PTEN Ubiquitina-
tion and Degradation by NEDD4-1 in
Cells
(A) Overexpression of NEDD4-1 enhances poly-
ubiquitination of PTEN. His-tagged PTEN,
HA-Ub, and an increasing amount of NEDD4-
1were cotransfected in 293T cells as indicated.
The ubiquitination of His-tagged PTEN was de-
tected as described in Figure 1A. The lower
panel shows expression of NEDD4-1.
(B) Overexpression of NEDD4-1 causes a de-
crease in PTEN protein level. As indicated,
NEDD4-1 with a C-terminal HA-tag or vector
alone was transfected in 293T cells by electro-
poration. After 24 hr, the cells were treated with
or without 50 mM MG132 for 4 hr as indicated.
Subsequently, the cells were harvested and
lysed, and the endogenous PTEN levels of indi-
vidual samples were detected by immunoblot-
ting. b-tubulin was used as the loading control.
PTEN levels (relative to tubulin) were quanti-
tated by densitometry.
(C) NEDD4-1 polyubiquitinates endogenous
PTEN and targets it for proteasomal degrada-
tion. As described in Experimental Procedures,
His-tagged ubiquitin and NEDD4-1-HA were
transfected into 293T cells as indicated. The
cells were treated with or without MG132 as in-
dicated and then harvested and lysed. Proteins
modified with His-tagged ubiquitin were pulled
down and subjected to immunoblotting against
PTEN.
(D) RNAi of NEDD4-1. The efficacy of several
human NEDD4-1 RNAi constructs (iN4A–
iN4C) was examined by immunoblotting
against HA-tag in HeLa cells that had been co-
transfected with NEDD4-1-HA and RNAi con-
structs as indicated. A LacZ RNAi construct
(iLacZ) was used as a control.
(E) Elimination of NEDD4-1 by RNAi increases PTEN level in cells. Individual RNAi constructs were cotransfected into HeLa cells with PTEN-HA as
indicated. The expressed PTEN-HA was detected by immunoblotting.
(F) NEDD4-1 overexpression decreases PTEN stability. As detailed in Experimental Procedures, PTEN plasmid was cotransfected with NEDD4-1 or
control plasmid as indicated. Cells were treated with cycloheximide and harvested at indicated time points. Subsequently, immunoblotting against
PTEN, NEDD4-1 (both HA-tagged), and tubulin control was performed.
(G) NEDD4-1 RNAi increases PTEN stability. PTEN was cotransfected with iN4A (NEDD4-1 RNAi) or control plasmid as indicated. Cells were treated
with cycloheximide and harvested at indicated time points. Subsequently, immunoblotting against PTEN and tubulin control was performed.NEDD4-1might contribute to the lowPTENprotein in these
samples. Therefore, we examined a cohort of invasive
human bladder cancer samples (87 cases) whose mRNA
array results and PTEN-IHC status were documented.
These samples showed relatively normal PTEN mRNA
levels (Figure 6B). Many of them had high NEDD4-1
mRNA levels, and a subset of these samples (12%) ex-
pressed NEDD4-1 mRNA levels more than 5-fold higher
than the median value (Figure 6B). At mRNA level, there
was no correlation between NEDD4-1 and PTEN expres-
sion. However, when analyzing the mRNA array and
PTEN-IHC data of these samples, an inverse correlation
between NEDD4-1 mRNA levels and PTEN protein levels
was observed with statistical significance (Figure 6C). Fur-
ther, when these samples were classified into two groups,
those with high PTEN protein levels and those with low
PTEN protein levels, the mean NEDD4-1 mRNA value ofthe latter group is 2-fold of the mean value of the other
group (data not shown). Therefore, we postulate that in
these human bladder cancer samples, overexpression of
NEDD4-1 contributes to the posttranslational downregu-
lation of PTEN.
Given that NEDD4-1 possesses oncogenic function, we
examined whether elimination of NEDD4-1 expression by
RNAi could inhibit tumor growth. We used two human
prostate cancer cell lines, DU-145 and PC3, for this pur-
pose. After RNAi, the cells were injected into athymic
nude mice, and the xenotransplanted tumor growth was
measured. We found that when DU-145 cells, which are
PTEN positive, were used as the tumor donor, NEDD4-1
RNAi caused a clear inhibition of tumor growth compared
with control LacZ RNAi (Figure 7A). However, when PC3
cells, which are PTEN negative, were used as the tumor
donor, NEDD4-1 RNAi had no effect on tumor growthCell 128, 129–139, January 12, 2007 ª2007 Elsevier Inc. 133
Figure 5. NEDD4-1 Potentiates Cell
Transformation in a PTEN-Dependent
Manner
(A) NEDD4-1 regulates AKT phosphorylation.
RNAi plasmid iLacZ or iN4A was transfected
into 293 cells by electroporation. Immunoblot-
ting against NEDD4-1, PTEN, phospho-AKT
(p-Akt), total AKT, and b-tubulin was performed
as indicated.
(B) Overexpression of NEDD4-1 in p53/ pri-
mary MEFs decreased endogenous PTEN
level. The MEFs were transfected with vector
control or NEDD4-1 (N4-HA) as indicated by
electroporation. The cells were lysed 24 hr
later. N4-HA and endogenous PTEN were
detected by immunoblotting. b-tubulin was
blotted as the loading control.
(C) Overexpression of NEDD4-1 promotes
Ras-induced cell transformation in p53/ pri-
mary MEFs. The p53/ primary MEFs were
infected with retroviruses encoding for no ec-
topic protein (vector), Ras, and/or NEDD4-1
(N4), as indicated. Soft-agar colony-formation assays were performed as described in Experimental Procedures. The pictures show the typical col-
ony-formation assay result.
(D) Overexpression of NEDD4-1 promotes cell transformation in a PTEN-dependent manner. The colony-formation assays were performed in both
p53/ primary MEFs and p53+/Pten/ primary MEFs. The plot represents the results from three independent experiments with standard deviation.(Figure 7A). Therefore, elimination of NEDD4-1 is effective
in inhibiting tumor growth in a PTEN-dependent manner.
This result suggests that NEDD4-1 might be a valuable
therapeutic target in treating PTEN-positive cancers.
DISCUSSION
In this study, we have identified NEDD4-1 as an E3 for the
tumor suppressor PTEN. NEDD4-1 can polyubiquitinate
PTEN and thus target PTEN for proteasomal degradation.
This finding opens a new avenue to study the roles of
PTEN in apoptosis, tumorigenesis, and other important
processes.
NEDD4-1 is a HECT-domain E3. It should be noted that
NEDD4-1 has been reported to be an E3 for multiple viral
Gag proteins (Blot et al., 2004; Strack et al., 2000), which
are exogenous. The close homolog of NEDD4-1, NEDD4-
2, cannot ubiquitinate PTEN; on the other hand, NEDD4-2
but not NEDD4-1 is the E3 for epithelial and cardiac volt-
age-gated sodium channels (Kamynina et al., 2001; Rou-
gier et al., 2005). How these two highly homologous en-
zymes possess distinct substrate specificity is of interest
for future study. Further, there are additional NEDD4-like
E3s with distinct functions in mammals as well as in other
organisms (Ingham et al., 2004). For example, NEDD4-
family proteins have been shown to downregulate Notch
signaling in Drosophila (Fostier et al., 1998) and the level
of DNp63a, a p53-related transcriptional factor, in zebra-
fish (Bakkers et al., 2005).
Importantly, our study indicates that NEDD4-1 can po-
tentiate tumorigenesis and that aberrant activation of
NEDD4-1 can downregulate PTEN function. Thus, the re-
lationship of NEDD4-1 with PTEN is similar to that of
Mdm2 with p53 in which the oncoprotein Mdm2 is an E3134 Cell 128, 129–139, January 12, 2007 ª2007 Elsevier Inc.for the tumor suppressor p53 (Bond et al., 2005; Brooks
and Gu, 2003; Michael and Oren, 2002). Interestingly,
posttranslational modification, such as phosphorylation
and acetylation, of both Mdm2 and p53 can regulate the
binding and activity of Mdm2 toward p53 (Bond et al.,
2005; Brooks and Gu, 2003; Michael and Oren, 2002).
Similar modes of regulation might also exist for NEDD4-
1 and PTEN. For example, PTEN can be phosphorylated,
and its phosphorylation has been implicated in its function
and stability (Adey et al., 2000; Leslie and Downes, 2004;
Torres and Pulido, 2001; Vazquez et al., 2000). Therefore,
PTEN phosphorylation might somehow modulate its own
ubiquitination by NEDD4-1. Further, NEDD4-1 possesses
multiple domain structures, suggesting that its enzymatic
activity could also be closely regulated.
Nevertheless, regulation of PTEN by NEDD4-1 may also
prove to be fundamentally different from that of p53 by
Mdm2. It is well known that p53 is a fast turnover protein,
while PTEN is a relatively stable protein. Thus, a cellular re-
quirement for higher p53 levels is met by inhibition of its
degradation. We propose that PTEN degradation is mod-
ulated in the opposite manner: PTEN is by default a stable
protein and its degradation is accelerated when needed.
This could be achieved by posttranslational activation of
NEDD4-1 function in addition to an increase of its expres-
sion level, as suggested by many of our observations. For
example, in certain cell lines, we observed stable PTEN
levels despite high levels of NEDD4-1 and that only
a very robust overexpression of NEDD4-1 could reduce
PTEN protein levels. NEDD4-1-mediated PTEN degrada-
tion appears to be deliberately affected by cell adhesion
and growth condition; notably, the potent PTEN ubiquiti-
nation activity of purified NEDD4-1 can be dramatically in-
hibited by HeLa cell extracts in vitro, suggesting dominant
Figure 6. Reverse Correlation of NEDD4-1 and PTEN Levels in Cancer Samples
(A) High levels of NEDD4-1 inversely correlate with a further decrease of PTEN levels in a mouse prostate cancer model. The panel shows a typical
result of PTEN, NEDD4-1 (N4), and p-Akt IHC staining ofPtenhy/mouse prostate tissues. The IHC shows that high NEDD4-1 expression levels always
correlate with low PTEN levels that in turn correspond with high p-Akt and prostate-tumor initiation (p value < 0.001; calculated by chi-square test).
Glands with tumor (tm) and normal glands (nl) are indicated.
(B) The mRNA levels of NEDD4-1 and PTEN in a cohort of 87 invasive human bladder cancer samples. The mRNA levels were measured using Affy-
metrix GeneChip Plus 2.0.
(C) Reverse correlation of NEDD4-1 mRNA levels with PTEN protein levels in the human bladder cancer samples. The 87 samples were classified into
two groups (low NEDD4-1, 40 samples; and high NEDD4-1, 47 samples) based on the NEDD4-1 mRNA level of each sample relative to the mean
NEDD4-1 mRNA value of the whole cohort. Then the PTEN-IHC status of the two groups was plotted. The inverse correlation of NEDD4-1 mRNA
levels with PTEN protein levels in these samples is statistically significant with a p value of 0.04 calculated by both chi-square and Mann-Whitney
tests.posttranslational regulation of NEDD4-1 (X.W. and X.J.,
unpublished data). Furthermore, NEDD4-1 can also cause
PTENnuclear transport via catalyzing PTENmonoubiquiti-
nation (Trotmanet al., 2007 [this issueofCell]). Bydoing so,
NEDD4-1might be involved in regulating the nuclear func-
tion of PTEN such as maintenance of chromosomal integ-
rity (Shen et al., 2007 [this issue of Cell]). Intriguingly, nu-
clear transport of PTEN may protect PTEN from being
further polyubiquitinated by NEDD4-1 (a predominantly
cytoplasmic protein) and subsequently degraded by pro-
teasome. Therefore, NEDD4-1 might modulate PTEN
function both positively and negatively, depending on the
amount, activation, and localization ofNEDD4-1. Taken to-
gether, while we have identified NEDD4-1 as the E3 for
PTEN, this finding in turn raises many other important
questions, such as: How is NEDD4-1 activity regulated in
vivo? And what physiological triggers can induce
NEDD4-1-mediated PTEN downregulation versus nuclear
translocation?
Interestingly, while p53 loss or Mdm2 hyperactivation or
amplification could result in comparable outcomes favor-
ing tumor progression, NEDD4-1 might play a more com-
plex role in PTEN-loss-driven tumorigenesis: in contrast to
p53 loss, although reductions in PTEN levels have dra-
matic consequences on carcinogenesis (Trotman et al.,2003), the complete loss of PTEN triggers a cell-autono-
mous senescence response that antagonizes tumor
growth (Chen et al., 2005). Thus, strong NEDD4-1 activity
might be promoting tumorigenesis in a PTEN-heterozy-
gous background more effectively than complete PTEN
loss because NEDD4-1 could attenuate PTEN function
and thereby enhance proliferation without triggering
senescence. Considering that a large fraction of primary
human cancers (for example, about 70% of prostate can-
cers [Gray et al., 1998; Whang et al., 1998]) display loss of
only one PTEN allele, we propose that they are at risk
of carcinogenesis driven by high NEDD4-1 activity
(Figure 7B, red arrows). Conversely, these cancers may
benefit significantly from therapies specifically targeting
NEDD4-1 (Figure 7B, green arrows).
EXPERIMENTAL PROCEDURES
Preparation of Recombinant Proteins
The plasmids pT7-UbcH5c and pET28a-PTEN-HA (C-terminal HA-
tagged) were transformed into E. coli strain BL21 (DE3). The recombi-
nant proteins were expressed and purified by Ni-NTA affinity chroma-
tography according to standard procedures. Recombinant PTEN was
further purified using a 1 ml HiTrap SP column (Amersham) and dia-
lyzed against buffer A (20 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM
DTT). The purified proteins were stored at 80C in aliquots. TheCell 128, 129–139, January 12, 2007 ª2007 Elsevier Inc. 135
Figure 7. NEDD4-1 RNAi Inhibited Xeno-
transplanted Tumor Growth in a PTEN-
Dependent Manner
(A) The human prostate cancer cell lines, DU-
145 (PTEN-positive) and PC3 (PTEN-negative),
were stably infected with NEDD4-1 RNAi and
the control LacZ RNAi retroviruses. The in-
fected cells were subcutaneously injected into
athymic nude mice and the xenotransplanted
tumor growth was measured as described in
Experimental Procedures.
(B) A model for the potential function of
NEDD4-1 in prostate tumorigenesis. After loss
of one allele of PTEN, aberrant upregulation of
NEDD4-1 function will further decrease PTEN
protein level and thus accelerate cancer devel-
opment. Upregulation of NEDD4-1 might lead
to malignancy more rapidly than a complete
loss of PTEN gene because the latter will trigger
INK4a- and p53-dependent senescence (Chen
et al., 2005). NEDD4-1 offers a new entry point
for therapeutic intervention that could arrest
tumorigenesis in cooperation with the senes-
cence response.plasmid pGEX4T1-PTEN-HA was used to express recombinant GST-
PTEN in BL21 strain according to standard procedures. For purifica-
tion with glutathione Sepharose, after the recombinant protein was
bound to the column equilibrated with buffer A, the column was
washed with 103 column volume of buffer A supplemented with
500 mM NaCl. After washing again with buffer A, the recombinant pro-
tein was eluted with buffer A containing 15 mM reduced glutathione.
The eluant was further purified with a 1 ml HiTrap Q column (Amer-
sham). The purified GST-PTEN-HA was dialyzed against buffer A
and stored at 80C in small aliquots.
In Vitro Ubiquitination of PTEN
The reaction was carried out at 30C for 1 hr in 15 ml reaction buffer
(40mMTris-HCl, pH 7.5, 2mMDTT, 5mMMgCl2) containing the follow-
ing components: 10 mg of ubiquitin (Boston Biochem, #U-100), 20 nM
human E1 (Boston Biochem, #E302), 500 nM of recombinant UbcH5c,
2 mM ubiquitin aldehyde (Boston Biochem, #U-201), 5 mM ATP or
ATPgS, and 150 ng of GST-PTEN. HS100 or different chromatographic
fractions were added as E3 sources as indicated in individual experi-
ments. The reaction was terminated by adding 0.8 ml pull-down buffer
(20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 1% Triton X-100, 0.02% BSA,
and 5 mM b-mercaptoethanol). After addition of 8 ml of glutathione Se-
pharose 4B, the samples were rotated at room temperature for 40 min.
The beads were washed with 1 ml of pull-down buffer five times. The
proteins bound to beads were released by boiling in 30 ml of 23
SDS-PAGE sample buffer for 5 min. The samples were then resolved
by 8%SDS-PAGE followed by immunoblot analysis using amonoclonal
antiubiquitin antibody (BDBiosciences, #550944). In the reactions using
C-terminal HA-tagged recombinant PTEN instead of GST-PTEN as
substrate, all the components were the same as described above
except that 50 ng of recombinant PTEN-HA was added to replace
GST-PTEN. After ubiquitination reaction, the samples were directly
boiled with SDS-PAGE loading buffer and analyzed by immunoblotting
against HA-tag (Babco, HA.11).
Purification and Identification of PTEN E3 Activity from HS100
All purification steps were carried out at 4C, and chromatographywas
performed with an Amersham FPLC system. HS100 in buffer A (20mM136 Cell 128, 129–139, January 12, 2007 ª2007 Elsevier Inc.Tris-HCl, pH 7.5, 50mMNaCl, 1mMDTT) supplementedwith protease
inhibitors was prepared from large-scale cell culture purchased from
National Cell Culture Center. For the purification, 315 ml of HS100
(1.5 g total protein) was applied to a Q Sepharose column (60 ml
bed volume) equilibrated with buffer A. After washing the column
with buffer A containing 0.15 M NaCl, the PTEN E3 activity was eluted
into 120 ml of buffer A containing 0.35 M NaCl (480 mg protein). The
activity was then subject to 20%–50% (saturation) ammonium sulfate
precipitation. The protein pellet that contained the activity was dis-
solved in 40 ml buffer A (199 mg protein), and then ammonium sulfate
concentration was adjusted to 15%. The activity was subject to two
runs through a 5 ml HiTrap Phenyl Sepharose HP column (Amersham)
equilibrated with 15% ammonium sulfate in buffer A. After washing the
column with 10% ammonium sulfate, the activity was eluted with a
10%–0% gradient of ammonium sulfate in 80 ml buffer A followed by
20 ml buffer A. Fractions of 4 ml were collected, dialyzed, and assayed
for activity. The fractions containing the activity peakwere pooled (3.85
mg protein) and further fractionated with a 2 ml Hydroxyapatite (Bio-
Rad) column by using a 3–200 mM phosphate gradient in 30 ml buffer
B (20 mM HEPES, pH 7.5, 10 mM KCl, 1 mM DTT). Fractions of 2 ml
were collected, dialyzed, and assayed for activity. Then the activity
fractions were combined (1.07 mg protein) and fractionated with
a 1 ml HiTrap Heparin Sepharose HP column. The activity was eluted
by a gradient of 0–300 mM NaCl in 20 ml buffer A. Fractions of 1 ml
were collected, dialyzed, and assayed for activity. The active fractions
were combined and underwentmultiple runs through a 25ml Superdex
200 gel-filtration column in buffer A plus 50 mM NaCl. The activity
fractions were combined and resolved by a Mono Q column with
a 150–350 mM NaCl gradient in 20 ml buffer A. Fractions of 1 ml
were collected. After dialysis, activity assays were performed using
2 ml of each fraction, and SDS-PAGE followed by silver staining was
performed using 15 ml of each fraction. A single protein band cor-
relating to the PTEN E3 activity was identified. The individual Mono
Q fractions containing the purified activity were concentrated, resolved
by SDS-PAGE, and stained with Coomassie blue. The protein band
was subject to protein identity determination by performing MS analy-
sis (MALDI-TOF-MS/MS). The activity was identified as human
NEDD4-1.
Cloning of Full-Length NEDD4-1
HeLa cell genomic DNA was prepared as described in Sambrook and
Russell (2001). While using it as template, nest PCR was performed to
obtain DNA sequence containing the N-terminal fragment of NEDD4-1,
a GC-rich sequence. First-round PCR used primers AATATTAAAAAG
CATGATTATTCC and TCGTCCTCCAGGAGCCCGA. The second-
round PCR used primers ATAACCTTATTCCACAGGAGG and ACACC
TCCACCGCGCAAGT. The C-terminal fragment of NEDD4-1 was am-
plified by PCR from clone KIAA0093 using primers CTCCACAGTTG
CCTGCCCT and GCCCTCGAGCTAATCAACTCCATCAAAGCC (30-
XhoI). The two PCR products overlap with each other for 66 bp.
Then by mixing the N-terminal and C-terminal PCR fragments for a
template and using primer 50-EcoRI (CCGGAATTCTATGGCACAAAG
CTTACGATTGC) and primer 30-XhoI, the full-length NEDD4-1 was am-
plified by PCR and cloned into pCDNA3.1 using EcoRI and XhoI sites.
For NEDD4-1-HA construct, a HA-tag was inserted at the C terminus
by PCR. All constructs were verified by DNA sequencing.
NEDD4-1 RNAi Constructs
The shRNA constructs against human NEDD-1 were generated using
pSUPER.retro vector according to manufacturer’s procedure (Oli-
goEngine). The NEDD4-1 DNA sequences used in the RNAi constructs
are: 50TGGCGATTTGTAAACCGAA30 (iN4A); 50TGCAGAACAGGCTG
AGGAA30 (iN4B); and ATGAAACTTCGCCGAGCAA (iN4C).
Transfection and In Vivo PTEN-Ubiquitination Assay
Cell-culture transfection was performed using polyethylenimine (PEI)
reagent or, where indicated, electroporation approach (Amaxa) for
high transfection efficiency (>65%). For in vivo PTEN-ubiquitination as-
say, PEI transfection was performed when 293T cells in 10 cm plates
reached 50% confluence. Plasmids encoding for PTEN, NEDD4-1,
and HA- or His-tagged ubiquitin were used in transfection as indicated
in individual experiments. Twenty-four hours after transfection, cells
were treated with or without 25 mM proteasome inhibitor MG132 (Cal-
biochem) for 6 hr. The cells were washed with PBS, pelleted, and lysed
in 0.1 ml of PBS plus 1% NP-40, 25 mM MG132, 2 mM ubiquitin alde-
hyde, and protease-inhibitor cocktail. The lysates were centrifuged
to obtain cytosolic proteins. Subsequently, we followed a published
protocol (Treier et al., 1994) withminor modifications. Briefly, individual
samples were diluted with 1 ml of guanidine buffer (GB; 6 M guanidine,
0.1 M sodium phosphate, pH 8.0, 0.2% Titon-X100, 10 mM imidazole)
before addition of 20 ml TALON cobalt transition metal beads (BD Bio-
sciences) that were prewashed with GB. After rotating at 4C for 3 hr,
the beads were washed twice with 1 ml of GB followed by two washes
with 1 ml of GB/TI (GB/TI volume ratio 1:3; buffer TI is 20 mM Tris-HCl,
pH 6.8, 0.2% Titon-X100, 20 mM imidazole, 0.2% SDS). Then the
beads were washed twice with TI followed by two washes with TI
plus 1 M NaCl. After another wash with TI, the supernatant was com-
pletely removed with thin tips. The proteins were released from the
beads by boiling in 40 ml of 23 SDS-PAGE sample buffer plus 200
mM imidazole for 10 min. Twenty-five microliters of the samples
were subjected to immunoblot against antibodies as specified in
individual experiments.
Cycloheximide Chase Experiments
To examine the effect of NEDD4-1 overexpression on PTEN degrada-
tion, three 10 cm plates of HeLa cells were cotransfected with 2 mg/
plate of PTEN plasmid and 6 mg/plate of NEDD4-1 plasmid or control
plasmid. To examine the effect of NEDD4-1 RNAi on PTEN degrada-
tion, three 10 cm plates of HeLa cells were cotransfected with
0.8 mg/plate of PTEN plasmid and 3.2 mg/plate of RNAi construct
against human NEDD4-1 (iN4A) or control plasmid. Ten hours after
transfection, the cells from the triplicate plates were pooled together
and replated into four 6 cm plates to minimize the variation in transfec-
tion among the plates. Twelve hours after replating, 50 mg/ml of cyclo-
heximide was added to the 6 cm plates, and the cycloheximide treat-
ment was terminated at 0, 3, 6, and 9 hr time points as indicated. Thecell lysates were made, and protein concentration was determined.
Subsequently, 20 mg of total protein from each sample, except 60 mg
of total protein from the RNAi vector control samples, were analyzed
by immunoblotting as indicated.
Soft-Agar Colony-Formation Assay
Retroviruses were generated using pBABE-puro vector alone, pBABE-
puro-NEDD4-1, and pBABE-puro-Ras. Primary MEFs (cultured for 3
passages after isolation from mice) were plated in 10 cm plates (2 3
105/plate). After overnight incubation, they were infected by three
rounds of infection (4 hr each round) with indicated retroviruses.
Forty-eight hours after infection, cells were allowed to grow for 3
days in medium containing 2 mg/ml puromycin. After recovering from
puromycin selection for 12 hr in puromycin-free medium, viral-infected
cells were trypsinized and plated for soft-agar colony-formation assay.
For each assay, 53 105 viral-infected cells were plated with soft-agar
medium to individual wells in 6-well plates. The plates were incubated
for 2 to 3 weeks, and phase-contrast microscopic pictures were taken
for each sample using a digital camera coupled to a microscope to
show colony formation. Quantification and standard deviation were
obtained from results of three independent experiments.
Human Cancer Tissues and Microarray Analysis
Tumor tissues and clinical data were obtained through an IRB-ap-
proved protocol at Memorial Sloan-Kettering Cancer Center. Tumors
were microdissected to ensure that at least 70% of cells present
were tumor. RNA was extracted using Trizol (Invitrogen, Carlsbad,CA)
followed by cleanup with RNeasy columns (QIAGEN, Valencia, CA).
Double-stranded cDNA was produced using a ds cDNA synthesis kit
(Invitrogen) followed by production of labeled RNA probe using an
in vitro transcription kit (Enzo Diagnostics, Farmingdale, NY). Hybridiza-
tion, washing, and imaging of Affymetrix U133 Plus v. 2.0 microarrays
(Affymetrix, Santa Clara, CA) were performed according to manufac-
turer’s protocols. Microarray data were normalized, background sub-
tracted, and log transformed using the robust multiarray average
(RMA) method (Irizarry et al., 2003) within bioconductor for R (Gentle-
man et al., 2004).
IHC of Mouse Prostates
IHC was carried out with the automated staining processor (Ventana
Medical Systems, AZ) for mouse prostates as previously described
(Trotman et al., 2003) using the following antibodies: rabbit anti-
p-Akt (Ser473, IHC-specific; Cell Signaling Technology, Inc., # 9277),
rabbit anti-PTEN (Ab-2; NeoMarkers), anti-Nedd4 (Upstate, # 07-
049). For correlation of PTEN and NEDD4-1 status in Ptenhy/ mice,
single prostate glands on a total of nine adjacent sections from two
6-month-old animals were classified for NEDD4-1 and PTEN high or
low staining. A total of 16 glands were scored, yielding an inverse cor-
relation for PTEN and NEDD4-1 level as follows: no gland with PTEN
high/NEDD4-1 high or PTEN low/NEDD4-1 low; 11 glands with PTEN
high/NEDD4-1 low (normal glands); 5 glands with PTEN low/NEDD4-
1 high (tumor glands; p-Akt-positive). The statistical significance of
this inverse correlation was calculated using a chi-square analysis
(p < 0.001).
Xenotransplantation
DU-145 cells and PC3 cells were infected with iN4A or iLacZ pSUPER
retrovirus, selected with 2 mg/ml puromycin for 4 days, and allowed to
recover in the absence of puromycin. Subsequently, 106 DU-145 or
PC3 tumor cells bearing NEDD4-1 RNAi or LacZ RNAi retroviruses
as indicated were suspended in 100 ml 10% FCS and 100 ml Matrigel
(BD Biosciences) and subcutaneously injected into the right flank of
6-week-old athymic nude mice (NCRNU-M, Taconic Farms Inc.) in
triplicates. Every 3 days tumor size was measured with a caliper,
and volumes were calculated as L3W23 0.52, where L is the longest
diameter and W is the shortest diameter.Cell 128, 129–139, January 12, 2007 ª2007 Elsevier Inc. 137
Supplemental Data
Supplemental Data include four figures and can be found with this
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